# OnCo record car-t-manufacturing-process (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/car-t-manufacturing-process/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "car-t-manufacturing-process" ;
  schema:name "Autologous CAR-T manufacturing, batch by batch"@en ;
  schema:description "Each CAR-T dose is a separate factory run for one patient: collect their T cells, activate them, add the CAR gene with a virus, grow them for a week or two, freeze, test and ship them back. The steps, the failure points and the waiting list are all here."@en ;
  schema:url <https://onco.cc/technologies/car-t-manufacturing-process/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-development-chimeric-antigen-receptor-car-t-cell-products>, <https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271>, <https://en.wikipedia.org/wiki/Chimeric_antigen_receptor_T_cell> ;
  onco:status "standard-of-care" ;
  onco:tag "manufacturing-wave" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/follicular-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/apheresis-starting-material/>, <https://onco.cc/technologies/viral-vector-manufacturing/>, <https://onco.cc/technologies/closed-automated-cell-manufacturing/>, <https://onco.cc/technologies/cell-therapy-cold-chain/>, <https://onco.cc/technologies/cell-therapy-release-testing/>, <https://onco.cc/technologies/cell-therapy-orchestration-software/>, <https://onco.cc/technologies/point-of-care-cell-manufacturing/>, <https://onco.cc/technologies/allogeneic-cell-banks/>, <https://onco.cc/technologies/single-use-bioprocessing/>, <https://onco.cc/technologies/car-t/> ;
  onco:drugs <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/brexucabtagene-autoleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/idecabtagene-vicleucel/>, <https://onco.cc/drugs/ciltacabtagene-autoleucel/>, <https://onco.cc/drugs/obecabtagene-autoleucel/>, <https://onco.cc/drugs/lifileucel/> ;
  onco:companies <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/gilead/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/legend-biotech/>, <https://onco.cc/companies/autolus/>, <https://onco.cc/companies/miltenyi-biotec/>, <https://onco.cc/companies/cytiva/>, <https://onco.cc/companies/lonza/>, <https://onco.cc/companies/cellares/>, <https://onco.cc/companies/immunoact/> ;
  onco:terms <https://onco.cc/terms/vein-to-vein-time/>, <https://onco.cc/terms/apheresis/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/> .